0001209191-20-058830.txt : 20201117
0001209191-20-058830.hdr.sgml : 20201117
20201117173930
ACCESSION NUMBER: 0001209191-20-058830
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201116
FILED AS OF DATE: 20201117
DATE AS OF CHANGE: 20201117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brege Laura
CENTRAL INDEX KEY: 0001365619
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 201322207
MAIL ADDRESS:
STREET 1: C/O ONYX PHARMACEUTICALS, INC.
STREET 2: 2100 POWELL STREET
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-16
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001365619
Brege Laura
C/O PACIRA BIOSCIENCES, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
1
0
0
0
Common Stock
2020-11-16
4
M
0
12000
13.98
A
19921
D
Common Stock
2020-11-16
4
S
0
12000
65.95
D
7921
D
Stock Option (Right to Buy)
13.98
2020-11-16
4
M
0
12000
0.00
D
2021-06-02
Common Stock
12000
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.930 to $66.015, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested and became exercisable in 24 equal monthly installments beginning on July 2, 2011.
/s/ Kristen Williams, Attorney-in-Fact
2020-11-17